Sanifit Overview
- Year Founded
-
2007
- Status
-
Acquired/Merged
- Employees
-
31
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$236M
- Investors
-
1
Sanifit General Information
Description
Operator of a clinical-stage biopharmaceutical company intended to focus on treatments for progressive vascular calcification disorders. The company's drugs treat cardiovascular diseases linked to calcification in the end-stage renal disease population undergoing hemodialysis, thereby enabling patients on dialysis to be treated for heart disease.
Contact Information
Website
www.sanifit.comCorporate Office
- ParcBIT - Ctra. Valldemossa
- Km 7.4, Building Europa, 2nd Floor
- 07121 Palma
- Spain
Corporate Office
- ParcBIT - Ctra. Valldemossa
- Km 7.4, Building Europa, 2nd Floor
- 07121 Palma
- Spain
Sanifit Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Merger/Acquisition | 22-Nov-2021 | $236M | Completed | Generating Revenue | ||
| 14. Later Stage VC | 18-Nov-2020 | Completed | Generating Revenue | |||
| 13. Debt - General | 06-Aug-2020 | Completed | Generating Revenue | |||
| 12. Later Stage VC (Series D) | 26-Jun-2019 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series C) | 16-Nov-2018 | Completed | Generating Revenue | |||
| 10. Later Stage VC | 11-Oct-2017 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 21-Oct-2016 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series C) | 08-Sep-2015 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series B) | 21-Aug-2014 | $4.82M | $5.25M | Completed | Generating Revenue | |
| 6. Grant | 01-Jan-2014 | $431K | Completed | Generating Revenue |
Sanifit Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Ordinary | ||||||||
| Ordinary | 24,411,518 | $0.011795 | $1.26 | $1.26 | 1x | $1.26 | 21.54% | |
| Series B | 4,246,263 | $0.011795 | $1 | $1 | 1x | $1 | 3.75% |
Sanifit Comparisons
Industry
Financing
Details
Sanifit Competitors (73)
One of Sanifit’s 73 competitors is Cytokinetics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cytokinetics | Formerly VC-backed | South San Francisco, CA | ||||
| Walden Biosciences | Venture Capital-Backed | Cambridge, MA | ||||
| Prothena | Corporation | Dublin, Ireland | ||||
| uniQure | Formerly VC-backed | Amsterdam, Netherlands | ||||
| Geron | Formerly VC-backed | Foster City, CA |
Sanifit Patents
Sanifit Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025162971-A1 | Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification | Pending | 31-Jan-2024 | ||
| US-20260337212-A1 | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification | Pending | 29-Jul-2022 | ||
| WO-2024023359-A1 | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification | Inactive | 29-Jul-2022 | ||
| US-20260337211-A1 | Ip5 substituted compounds | Pending | 29-Jul-2022 | ||
| WO-2024023360-A1 | Ip5 substituted compounds | Inactive | 29-Jul-2022 | C07F9/117 |
Sanifit Signals
Sanifit Former Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alta Life Sciences | Venture Capital | Minority | ||
| Andera Partners | PE/Buyout | Minority | ||
| Baxter Ventures | Corporate Venture Capital | Minority | ||
| Caixa Capital Risc | Corporate Venture Capital | Minority | ||
| Columbus Venture Partners | Venture Capital | Minority |
Sanifit FAQs
-
When was Sanifit founded?
Sanifit was founded in 2007.
-
Where is Sanifit headquartered?
Sanifit is headquartered in Palma, Spain.
-
What is the size of Sanifit?
Sanifit has 31 total employees.
-
What industry is Sanifit in?
Sanifit’s primary industry is Drug Discovery.
-
Is Sanifit a private or public company?
Sanifit is a Private company.
-
What is the current valuation of Sanifit?
The current valuation of Sanifit is .
-
What is Sanifit’s current revenue?
The current revenue for Sanifit is .
-
How much funding has Sanifit raised over time?
Sanifit has raised $238M.
-
Who are Sanifit’s investors?
Alta Life Sciences, Andera Partners, Baxter Ventures, Caixa Capital Risc, and Columbus Venture Partners are 5 of 19 investors who have invested in Sanifit.
-
Who are Sanifit’s competitors?
Cytokinetics, Walden Biosciences, Prothena, uniQure, and Geron are some of the 73 competitors of Sanifit.
-
When was Sanifit acquired?
Sanifit was acquired on 22-Nov-2021.
-
Who acquired Sanifit?
Sanifit was acquired by CSL Vifor.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process